| Newer mAb Bests Standard Therapy for Less Risky Renal Tx - MedPage Today |
|
|
MedPage Today Explain that alemtuzumab was effective at preventing early rejection episodes in renal transplant recipients undergoing an early glucocorticoid wean compared with basiliximab or antithymocyte globulin. |